<DOC>
	<DOCNO>NCT00150943</DOCNO>
	<brief_summary>Background : Atherosclerotic renal artery stenosis ( ARAS ) associate progressive loss renal function one important cause renal failure elderly . Current treatment include restoration renal arterial lumen endovascular stent placement . However , treatment affect damage cause ARAS due stenosis ensue post-stenotic ischemia . ARAS patient severe general vascular disease . Atherosclerosis hypertension also damage kidney parenchyma cause renal failure . Medical treatment focus latter . Lipidlowering drug ( statin ) could reduce renal failure progression could reduce overall high cardiovascular risk . The additional effect preserve renal function stent placement compare medical therapy alone unknown . Therefore , STAR-study aim compare effect renal artery stent placement together medication vs. medication alone renal function ARAS patient . Method : Patients ARAS ≥50 % renal failure ( creatinine ( Cr ) clearance &lt; 80 mL/min/1.73 m2 ) randomly assign stent placement medication medication alone . Medication consist statin , anti-hypertensive drug antiplatelet therapy . Patients follow 2 yr extend follow-up 5 yr . The primary outcome study reduction Cr clearance &gt; 20 % compare baseline . This trial include 140 patient .</brief_summary>
	<brief_title>Stenting Renal Dysfunction Caused Atherosclerotic Renal Artery Stenosis</brief_title>
	<detailed_description>This randomize , multicenter trial patient ostial ARAS renal failure . Patients randomize : ( ) medical treatment consist antihypertensive , lipid-lowering antiplatelet therapy plus advice stop smoking ; ( ii ) medical treatment outline ( ) additional stent placement . Patients ostial ARAS , Cr clearance &lt; 80 mL/min/1.73m2 accord Cockcroft Gault formula stable blood pressure ( BP ) control enrol trial . Ostial ARAS define luminal reduction ≥50 % renal artery within 1 cm aortic wall , presence atherosclerotic change aorta . Stenosis evaluation perform CT-angiography , MR angiography intra-arterial angiography . Medical therapy : Irrespective baseline serum cholesterol value , patient treat lipid-lowering therapy : 10 mg atorvastatin well tolerate dose double final dose 20 mg. Any lipid-lowering medication currently use discontinue replaced atorvastatin . Hypertension treat follow drug : thiazide diuretic , calcium antagonist , beta-blocker alpha-blocker . ACE-inhibitors/angiotensin-II-antagonists together increase loop diuretic dos , use last resort antihypertensive treatment class antihypertensive agent fail . The target BP &lt; 140/90 mmHg . Patients receive anti-platelet therapy , aspirin 75-100 mg/od . Considering smoke major renal risk factor , smoker advise stop . Stent medical therapy : Medical therapy identical two treatment arm . In stent group , patient start aspirin 75-100 mg/od day admission . The stent ( Palmaz-Corinthian IQ/Palmaz Genesis , Johnson &amp; Johnson Medical , NV/SA ) place in-patient admission accord standardize protocol . Randomisation do per participate centre stratify unilateral bilateral abnormality . An unilateral abnormality define unilateral ostial stenosis side normal renal artery truncal stenosis ( truncal stenosis nearly always easy dilate angioplasty ) . All patient consider bilateral abnormality Clinical follow-up schedule 1 , 3 every 3 month first 2 yr every 6 month 5 yr follow-up complete . Economic data assess 3 mths every 3 mths 2 yr . Quality life measure standardized SF-36 EQ-5D health questionnaire , 1 mth every 6 mths 2 yr . Indications stent placement medically treat patient re-angiography balloon dilatation stent stented patient : ( ) persistent &gt; 20 % reduction Cr clearance ; ( ii ) therapy refractory hypertension ( defined office BP &gt; 180/100 mmHg three follow-up visit subsequently mean daily BP &gt; 160/95 mmHg 24 hr ambulant BP monitoring , maximum dose class antihypertensive ) ; ( iii ) pulmonary edema presence bilateral renovascular disease normal slightly impaired leave ventricular function echocardiography combination ACE-inhibitors/angiotensin-II antagonist intolerance define fall estimate Cr clearance &gt; 20 % ; ( iv ) malignant hypertension ( define fundus grade III/IV ) . Analysis result : The difference proportion patient progressive renal dysfunction treatment arm assess include 95 % confidence interval ( 95 % CI ) . Mean change difference renal function change , include 95 % CI report . With multivariate logistic regression analysis effect two treatment strategy evaluate , also whether independent effect age , smoking , proteinuria , bilateral unilateral renal artery stenosis , BP renal function baseline .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<criteria>Age &gt; 18 year Ostial atherosclerotic renal artery stenosis ≥50 % CTA , MRA intraarterial angiography Estimated creatinine clearance &lt; 80 ml/min/1.73m2 accord Cockcroft Gault formula , two occasion within one month Declined informed consent Proven cholesterol embolisation previous intervention Renal artery diameter &lt; 4mm Estimated creatinineclearance &lt; 15ml/min/1.73m2 Diabetes Mellitus proteinuria &gt; 3g/24h Any know cause renal failure ischemic nephropathy Pulmonary oedema presence bilateral renovascular disease combination intolerance ACEinhibitors/ AngiotensinII antagonist define fall estimate creatinine clearance &gt; 20 % Malignant hypertension ( fundus grade III/IV ) Myocardial infarction CVA &lt; 3 month plan date inclusion Contraindication use atorvastatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Renal artery stenosis</keyword>
	<keyword>Stent</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>